Dr. Alan Rosenberg MD, FRCPC, SOM, FCAHS

Dr. Alan Rosenberg graduated from the University of Saskatchewan’s College of Medicine. Following specialty training in pediatrics at the Universities of Toronto and Manitoba he did subspecialty training in pediatric rheumatology at the University of British Columbia. He returned to Saskatchewan in 1981 to establish the province’s first program in pediatric rheumatology to serve Saskatchewan children with arthritis and related rheumatic diseases. Since 1981 Dr. Rosenberg has directed the Pediatric Rheumatic Disease Research and Innovation Laboratory, University of Saskatchewan, among the world’s oldest, continuously maintained pediatric rheumatology research programs.

Dr. Rosenberg has held headships of the Department of Pediatrics, the Division of Rheumatology, and the Division of Pediatric Research.

Dr. Rosenberg’s research includes studies of childhood rheumatic diseases exploring how genetic, lifestyle, and environment interact to influence the occurrence and outcomes of disease and, by investigating the earliest origins of inflammatory-mediated chronic diseases, will generate new knowledge to guide disease cure and prevention strategies.

Dr. Rosenberg is an ardent proponent of promoting and facilitating transdisciplinary collaborations in child health research and leads and participates in national and international, multidisciplinary research consortia. His research program exemplifies how research agendas are propelled by curiosity and creativity, and by collaboration with a wide array of biomedical and non-biomedical investigators and with patients and communities. As a committed educator, Dr. Rosenberg aims to inspire and guide the next generations of care providers and researchers.

Dr. Rosenberg is a University of Saskatchewan Distinguished Professor, a Fellow of the Canadian Academy of Health Sciences, a Canadian Rheumatology Association Distinguished Rheumatologist awardee, and recipient of the Saskatchewan Order of Merit.

 

• Pediatric Rheumatic Diseases

• Childhood arthritis
• Childhood rheumatic diseases
• Autoimmunity
• Discovering the earliest origins of inflammation-mediated diseases
• Strategies for promoting disease prevention

• Rosenberg, AM. & Petty, RE. (2021). Structure and Function. In Petty RE., Laxer RM., Lindsley C., Fulhbrigge R., Mellins E. (Ed.), Textbook of Pediatric Rheumatology (pp.1-11). Philadelphia: Elsevier
• Rosenberg, AM., Jariwala, J. & Cron, R. (2021). Polyarticular Juvenile Idiopathic Arthritis. In Petty RE., Laxer RM., Lindsley C., Wedderburn L., Mellins E., Fuhlbirgge R. (Ed.), Textbook of Pediatric Rheumatology (pp.228-240). Philadelphia: Elsevier
• Nguyen, K., Barsalou, J., Basodan, D., et al. (2023). A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry. BMC Rheumatology
• Gibson, K., Brogemoller, B., Foell, D., et al. (2023). HLA-DPB1 is associated with ANCA- associated vasculitis in children. Arthritis and Rheumatology, 75(6): 1048-1057.
• Berard, R., Ng, H., Human, A., et al. (2023). Canadian Rheumatology Association recommendations for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Journal of Rheumatology, 50(3): 390-399.
• Lee, J.Y., Eng, S.W.M., Guzman, J., et al. (2022). A comparison of Juvenile Idiopathic Arthritis classification systems with the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh‐Out) cohort. Arthritis and Rheumatology, 74(8): 1409-1419.
• Heale, LD., Houghton, K., Rezaei, E., et al. (2021). Clinical and psychosocial stress factors are associated with decline in physical activity over time in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 19(1).
• Finch, SL., Rosenberg, AM., Kusalik, AJ., et al. (2021). Higher concentrations of vitamin D in Canadian children with juvenile idiopathic arthritis compared to healthy controls are associated with more frequent use of vitamin D supplements and season of birth. Nutrition Research, 92:139-149.
• Rezaei, E., Newkirk, MM., Li, Z., et al. (2021). Soluble low-density lipoprotein receptor-related protein 1 in juvenile idiopathic arthritis. Journal of Rheumatology, 48(5): 760-766.
• Chedeville, G., McGuire, K., Cabral, DA., et al. (2022). Parent‐reported medication side‐effects and their impact on health‐related quality of life in children with juvenile idiopathic arthritis. Arthritis Care and Research, 74:1567-1574.
• Batthish, M., Berard, R., Cabral, D., et al. (2020). A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry. Rheumatology (Oxford), 59(10): 2796-2805.
• Rezaei, E., Hogan, D., Trost, B., et al. (2020). Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. Rheumatology (Oxford), 59(9): 2402-2411.
• Stinson, JN., Lallou, C., Hundert, AS., et al. (2020). Teens Taking Charge: A randomized controlled trial of a web-based self-management program with telephone support for adolescents with juvenile idiopathic arthritis. Journal of Medical Internet Research, 22(7): e16234.
• Chhabra, A., Oen, K., Huber, AM., et al. (2020) Real-world effectiveness of common treatment strategies for juvenile idiopathic arthritis: results from a Canadian cohort. Arthritis Care and Research, 72:897-906.
• Rezaei, E., Hogan, D., Trost, B., et al. (2020). Associations of clinical and inflammatory biomarker clusters with juvenile idiopathic arthritis categories. Rheumatology (Oxford), 59(5): 1066-1075. 
• Batthish, M., Berard, R., Cabral, D., et al. (2020). A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry. Rheumatology (Oxford), 59(10): 2796-2805.
• Rosenberg, A. (2019). Do we need a new classification of juvenile idiopathic arthritis?. Clinical Immunology, 211: 108298. · Lee, J., Duffy, C., Guzman, J. et al. J. (2019). Prospective Determination of the Incidence and Risk Factors of New‐Onset Uveitis in Juvenile Idiopathic Arthritis: The
• Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort. Arthritis Care and Research, 71(11): 1436-1443. · Gibson, K., Morishita, K., Dancey, P., et al. (2019). Identification of novel Adenosine Deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis. Arthritis and Rheumatology, 71(10): 1747-1755.
• Maleki, F., Ovens, KL., Hogan, DJ., et al. (2019). Measuring consistency among gene set analysis methods: A systematic study. Journal of Computational Biology and BioInformatics, 17(5): 1940010. 
• Maleki, F., Ovens, K., McQuillan, I., et al. (2019). Gene Set Databases: A Fountain of Knowledge or a Siren Call?. ACM Transactions on Computer Systems, 269-278. 
• Cuvelier, G., Rubin, T., Juner, A., et al. (2019). Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency. Clinical Immunology, 205: 138-147.
• Guzman, J., Henrey, A., Loughin, T., et al. (2019). Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort. Journal of Rheumatology, 46(6): 628-635.
• Eng, S., Aeschlimann, F., van, Veenendall M., et al. (2019). Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: A prospective study with multilayer non-negative matrix factorization. PLOS Medicine, 16(2): e1002750.
• Maleki, F., Ovens, K., Rezaei, E., et al. (2019). Method Choice in Gene Set Analysis Has Important Consequences for Analysis Outcome. Biomedical Engineering Systems and Technologies, 3: 43-54.